Gilead Sciences Inc (GILD): Today's Featured Drugs Loser

Gilead ( GILD) pushed the Drugs industry lower today making it today's featured Drugs loser. The industry as a whole closed the day down 1.5%. By the end of trading, Gilead fell $1.21 (-2.4%) to $50.04 on average volume. Throughout the day, 5.1 million shares of Gilead exchanged hands as compared to its average daily volume of 6.7 million shares. The stock ranged in price between $49.74-$51.20 after having opened the day at $51.16 as compared to the previous trading day's close of $51.25. Other company's within the Drugs industry that declined today were: Anthera Pharmaceuticals ( ANTH), down 70.7%, Synta Pharmaceuticals ( SNTA), down 33.5%, NeurogesX ( NGSX), down 22.2%, and Vertex Pharmaceuticals ( VRTX), down 16.3%.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases worldwide. Gilead has a market cap of $38.15 billion and is part of the health care sector. The company has a P/E ratio of 15.2, equal to the average drugs industry P/E ratio and below the S&P 500 P/E ratio of 17.7. Shares are up 23.1% year to date as of the close of trading on Wednesday. Currently there are 18 analysts that rate Gilead a buy, no analysts rate it a sell, and five rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the positive front, Orexigen Therapeutics ( OREX), up 19.9%, Chelsea Therapeutics International ( CHTP), up 12.1%, Medgenics ( MDGN), up 10.1%, and ACADIA Pharmaceuticals ( ACAD), up 9.9%, were all gainers within the drugs industry with AstraZeneca ( AZN) being today's featured drugs industry winner.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).